|
Breast Cancer
|
|
ANZ 1601/BIG 16-02
A randomised phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised luminal A early breast cancer |
Recruitment one hold
|
|
TRIO033
(New Adjuvant Trials with LEE) Phase III clinical trial of ribociclib (LEE011) with endocrine therapy in the adjuvant treatment of HR +ve, HER2-ve early breast cancer
|
Recruitment on hold |
|
RAD1901-308
Elacestrant Monotherapy Vs. Standard of Care For The Treatment Of Patients With ER+/Her2- Advanced Breast Cancer Following Cdk4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicentre Trial
|
Recruitment on hold |
|
Glioblastoma
|
|
A phase III trial of extended temozolomide in newly diagnosed glioblastoma (EX-TEM)
|
Recruitment on hold |
|
Upper GI
|
|
SOM vs DXA
A prospective pilot study of body composition assessment in gastric and oesophageal cancers at St Vincent's Hospital
|
Recruitment on hold |
|
AG0407GR
A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer
|
Recruitment on hold |
|
Lower GI (Colon)
|
|
ctDNA-08
Circulating Tumour DNA Analysis Informing Aadjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study
|
Recruitment on hold |
|
Lower GI (Colorectal)
|
|
Shared chare of colorectal cancer survivors
|
Recruitment on hold |
|
Lower GI (Rectal)
|
|
ctDNA-11
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study
|
Recruitment on hold |
|
Non-Small Cell Lung Cancer (NSCLC)
|
|
CTC 0209 / ALTG 16/009
A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (ILLUMINATE)
|
Recruitment on hold |
|
MS200647_0005
A phase II multicentre randomized, open label controlled study of M7824 in combination with chemoradiation followed by consolidation with M7824 in comparison with chemoradiation followed by consolidation with Durvalumab or M7824 in participants with unresectable Stage III NSCLC
|
Recruitment on hold |
|
Pancreatic
|
|
ctDNA-09
Circulating tumour DNA analysis informing adjuvant chemotherapy in early stage Pancreatic cancer: A multi-centre randomised study (Dynamic-Pancreas)
|
Recruitment on hold |
|
2016.2
Pancreatic cancer: Understanding Routine Practice and Lifting End results (PURPLE) A Prospective Pancreatic Cancer clinical registry
|
Recruitment on hold |
|
8951-CL-5201
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
|
Recruitment on hold
|
|
Prostate
|
|
I3Y-MC-JPCM
A Phase 2, Randomised, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Pednisone with or without Abemaciclib in Patients with Metastatic Castration Resistant Prostate Cancer
|
Recruitment on hold
|
|
Esophageal
|
|
BGB-A317-306
A Randomized, Placebo-controlled, double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in combination with chemotherapy a First-Line Treatment in Patients with Unresectable, Locally advanced recurrent or metastatic Esophageal Squamous Cell Carcinoma
|
Recruitment on hold
|
|
Cutaneous Squamous Cell Carcinoma (CSCC)
|
|
R2810-ONC-1788
A Randomised placebo-controlled double blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
|
Recruitment on hold
|
|
Liver
|
|
CA209-9DW
Bristol-Myers Squibb, A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma
|
Recruitment on hold
|
|
Solid Tumors
|
|
42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations
|
Recruitment on hold
|
|
Multiple
|
|
DB-020-002
Phase 1 Randomised, double-blind, placebo controlled, multicentre study to evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics or Repeated doses of DB-020 in patients receiving Cisplatin
|
Recruitment on hold
|